摘要
目的研究缬沙坦对FAS、FAS-L在甲状腺功能亢进(甲亢)性心脏病大鼠心肌组织表达的影响。方法Sprage-Dawley(SD)大鼠40只,按随机数字表法分为对照组、L-甲状腺素组、缬沙坦小剂量组(L-甲状腺素+10 mg/kg缬沙坦)、缬沙坦大剂量组(L-甲状腺素+30 mg/kg缬沙坦)。L-甲状腺素组和缬沙坦干预组予L-甲状腺素0.5 mg/(kg.d)腹腔注射28 d建立甲亢模型,缬沙坦小剂量组在建模同时予缬沙坦10 mg/(kg.d)灌胃治疗,缬沙坦大剂量组每天灌服缬沙坦30 mg/(kg.d)。造模前后分别采取大鼠静脉血,用化学发光法检测血清TT3、TT4浓度;第28天解剖动物,测定各组大鼠心脏质量指数;收集左心室心肌组织分别行苏木素伊红染色和Masson染色观察左心室心肌组织形态结构、测定左心室细胞直径和胶原容积分数及免疫组化观察FAS、FAS-L的表达情况。结果与对照组相比,L-甲状腺素组大鼠心脏质量指数、心肌细胞直径、胶原容积分数增大,FAS、FAS-L蛋白表达明显增强,差异有统计学意义(P<0.05);而缬沙坦干预组上述心室重构指标明显改善,FAS、FAS-L蛋白表达下降,差异有统计学意义(P<0.05);而缬沙坦大、小剂量组之间上述指标比较,差异无统计学意义(P>0.05)。结论缬沙坦可通过调节FAS/FAS-L的表达,抑制心肌重构,具有保护心脏功能的作用。
Objectives To investigate the effects of valsartan on the expression of FAS and FAS-L in hyperthyroid cardiomyopathy rats. Methods New sprague-dawley rats were randomly divided into four groups （n=10 each） ： control group, L-thyroxine group （L-thyroxine alone）, valsartan low dose group （L-thyroxine ＋ valsartan 10 mg/kg） and valsarlan high dose group（L-thyroxine ＋ valsartan 30 mg/kg）. Rat models of hyperthyroidism were established by daily inlraperitoneal injections of L-thyroxine [ 0.5 mg/（kg. d）] in L-thyroxine group and valsartan groups for 28 days. At the same time, rats in valsartan low dose group received gastric lavage treatment of valsartan 10 mg/（k.d）, and rats in valsartan high dose group were drenched with valsartan 30mg/（kg.d）. Intravenous blood samples were collected before and after model establishment and plasma levels of TT3 and TF4 were measured by chemiluminescence method. All the rats were treated for 4 weeks, and at the end of the treatment, cardiac mass index was determined. Ventricular tissue was collected for heinatoxylin-eosin （H＆E） and masson stains. Cardiomyocyte diameter, eollagen volume fraction and structural changes were obtained. Protein expression of FAS and FAS-L in left ventricle was localized by immunohistochemistry and semi-quantified by pathological image analysis system. Results Compared with control group, cardiac mass index, cardiomyocyte diameter, collagen volume fraction and protein expression of FAS and FAS-L inL-thyroxine group significantly increased （P〈0.05）. Cardic mass index, cardiomyocyte diameter, collagen volume fraction and protein expression of FAS, FAS-L significantly decreased in valsartan groups （P〈0.05）. There were no significant differences of the above indexes between valsartan low dose group and valsartan high dose group （P〉0.05）. Conclusions Valsartan can effectively inhibit ventricular remodeling, ameliorate myocardial hypertrophy by decreasing the expression of FAS/FAS-L.
出处
《岭南心血管病杂志》
2013年第1期88-92,共5页
South China Journal of Cardiovascular Diseases
基金
无锡市医院管理中心医学科技发展基金资助面上项目(项目编号:YGM1012)
